Regulation & Legal

Krungsri Securities said the Social Security Board approved a gradual increase in the wage ceiling for insured persons under Section 33, from 15,000 baht to 17,500 baht in 2026, 20,000 baht in 2029, and 23,000 baht in 2032. The research team estimates that raising the wage ceiling from 15,000 baht to 17,500 baht during 2026-28 will increase the contribution base by 16.7% and generate additional revenue for the fund of about 3,825 baht per insured person per year. Considering only the four-case fund, which directly supports health benefits, it will add revenue of approximately 1,350 baht per insured person per year. Based on a sensitivity analysis assuming a roughly 10% increase in social security medical treatment fees for capitation, IPD treatment, and chronic disease risk burden, similar to the most recent adjustment on May 1, 2023, it is estimated to add a burden to the fund of about 301 baht per insured person per year, or 22% of the incremental revenue of the four-case fund. This reflects that the fund's increased revenue exceeds the higher treatment burden and increases the likelihood of future adjustments to medical treatment rates, which would be an upside for BCH and CHG. On October 19, 2026, the ad hoc subcommittee to review the criteria and rates for medical service payments to contracted hospitals in the social security system will meet to finalize the proposal to adjust social security medical treatment fees after three meetings. It will then propose to the Medical Board and the Social Security Board. The research team assesses the impact on the 2027 earnings forecasts of BCH and CHG under two scenarios. In the first scenario, only the capitation rate is raised by 10%, with an assumed incremental margin of 80%, which would increase 2027 earnings of BCH and CHG by about 11% and 9%, respectively, with additional value from the target price of BCH of about 0.60-0.70 baht and CHG of about 0.10-0.15 baht. In the second scenario, all three items are raised by 10%, with an assumed incremental margin of 70%, which would increase earnings of BCH and CHG by about 13% and 11%, respectively, with additional value from the target price of BCH of about 0.80-1.00 baht and CHG of about 0.15-0.20 baht. The research team maintains a bullish view on the hospital sector, with top picks BDMS (Buy, target price 25 baht) and PR9 (Buy, target price 24 baht), while BCH (Buy, target price 12 baht) stands out in the social security hospital group due to earnings having passed the trough and a high chance of benefiting from the increase in social security medical treatment rates.

SpaceX has agreed to acquire Grain Management's nationwide portfolio of low-band wireless spectrum licenses, advancing the Elon Musk-led company's effort to compete with Verizon Communications Inc., AT&T Inc. and T-Mobile Us Inc. The agreement covers spectrum in the 800 MHz band and remains subject to approval by the Federal Communications Commission; SpaceX says the licenses will complement Starlink Mobile's existing satellite capabilities with terrestrial connectivity. The FCC has also authorized SpaceX to deploy 15,000 next-generation Starlink satellites optimized for mobile connectivity, and together the spectrum acquisition and satellite expansion move the company closer to offering a more comprehensive mobile service. Musk made his ambitious prediction in an Oct. 8 post on X, saying he sees a path to SpaceX being worth orders of magnitude more than the current Earth economy. Investors should watch for regulatory approval, launch timelines, pricing announcements and evidence of customer adoption, as the next test is whether SpaceX can persuade consumers to switch networks or pay less to stay connected.

Foxconn Industrial Internet announced that the U.S. International Trade Commission declared on October 9 local time that it has formally launched a Section 337 investigation into patent infringement claims filed by Vicor Corporation of the United States. Vicor alleges that Foxconn Industrial Internet and its controlled subsidiaries infringed one of its patents for a vertical power delivery system. Foxconn Industrial Internet said that after an internal review, the products involved in this investigation are still in the internal validation and evaluation stage, and will not have a material impact on the company's current production, operations, or financial performance.

Baili Tianheng announced that the company recently received a Drug Clinical Trial Approval Notice issued by the National Medical Products Administration. The clinical trial of its self-developed, world-first bispecific antibody drug conjugate Yizekang, also known as luncoitab, in combination with radiotherapy for locally advanced unresectable head and neck squamous cell carcinoma and other solid tumors has been approved. To date, the drug has initiated more than 45 clinical trials in China and the United States, including 20 Phase III clinical studies, and 9 indications have been included in the breakthrough therapy designation list by the Center for Drug Evaluation.

Roche announced new one-year data from the Phase III MEERKAT and SANDCAT studies showing that investigational vamikibart sustained improvements in vision and reductions in macular thickness in adults with uveitic macular edema at 52 weeks compared with a sham procedure. The results were presented at the American Academy of Ophthalmology 2026 Annual Meeting in New Orleans. The FDA has accepted Roche's Biologics License Application for vamikibart for the treatment of UME, with an approval decision expected by July 2027; if approved, vamikibart would be the first non-steroid targeted treatment for UME. Regulatory submissions have also been filed and accepted in the European Union, China and Japan. In both trials, a numerically higher proportion of vamikibart-treated patients achieved vision gains than those on sham treatment on the primary endpoint, and key secondary endpoints showed sustained improvements in best corrected visual acuity and central subfield thickness. Vamikibart was well tolerated with a low incidence of treatment-related ocular adverse events and intraocular inflammation events, and approximately two-thirds of eligible patients required no retreatment after 16 weeks.

A court in Amsterdam on Saturday denied demands by shareholders of Philips for an investigation into the company over its handling of a massive product recall involving its sleep apnea and ventilator machines in 2021. The Enterprise Chamber of the Amsterdam Court of Appeal ruled in favor of the company, dealing a setback to a large group of Philips shareholders, including the Dutch investors' association, VEB, and several institutional investors. The shareholders called for a court inquiry after the Dutch medtech launched a recall of roughly 3.5M breathing machines in 2021 due to concerns that a polyurethane foam used in the devices could deteriorate and become toxic. The investors argued that the company failed to identify and address the issues promptly due to weaknesses in its internal systems, and alleged that the Philips board of directors was aware of the problems at the company's Respironics U.S. unit, which made the devices, well before the disclosures were made regarding the issue. The chamber said there is no reason to assume that Philips ought to have intervened at Respironics earlier, or that the Supervisory Board exercised insufficient oversight, and added that there is no sufficient basis to determine that Philips' disclosures to the investors were late, incorrect, or misleading. The chamber didn't rule on whether there were errors at Respironics or regarding the extent of liability for damages faced by investors.

Jim Cramer used the October 6 episode of Mad Money to argue that CVS Health Corporation has become too cheap to ignore after its stock plunged from $110 to $86, even as the company's earnings outlook improved. CVS reported second-quarter revenue of $106.1 billion, up 7.3% year over year, with adjusted EPS rising to $2.58 from $1.81 and GAAP diluted EPS climbing to $2.31 from $0.80, while the insurance business's medical benefit ratio improved to 87.4% from 89.9%. The company raised its full-year adjusted EPS guidance to $7.90 to $8.10 and its operating cash flow outlook to at least $11.5 billion, and management placed a reasonable floor under 2027 adjusted EPS at $8.44. Cramer said a possible 5% hit to next year's earnings should not send a stock down 22%, knocking nearly $30 billion off the company's market cap, especially not when CVS remains very strong. The uncertainty centers on Caremark, where the Centers for Medicare & Medicaid Services' July proposal would pay average sales price minus 33.4% for drugs acquired through the 340B program, and where the FTC's July settlement would separate manufacturer fees from drug list prices and add transparency and options to move away from rebate guarantees and spread pricing. CVS also said Caremark membership would decline in 2027 as contracts change and some insurance clients withdraw from markets. Using the October 7 closing price of $87.95 and the $8 midpoint of CVS's 2026 adjusted EPS guidance, the stock trades at approximately 11x this year's projected adjusted earnings, versus approximately 9.1x for Cigna based on its $278.51 closing price and its 2026 adjusted earnings guidance floor of $30.45. According to Insider Monkey's data, 88 hedge funds held CVS Health in the second quarter, compared with 84 in the first quarter, with Pzena Investment Management the most prominent shareholder at around 11.77 million shares and GQG Partners increasing its holdings by 25137% to 7.955 million shares, while short interest stood at 1.27% of the public float.

The US Food and Drug Administration granted Breakthrough Device designation to Natera's multi cancer early detection blood test, a move that reshapes how investors frame the company's diagnostics pipeline. The designation follows a strong run in Natera's share price, with a 30-day return of 21.31%, a 90-day move of 48.44%, a year-to-date gain of 75.10%, and a 1-year total shareholder return of 136.73%. The stock's latest close of $400.71 sits above the most followed fair value estimate of $355.93, which implies the shares are 13% overvalued under a 7.5% discount rate. By contrast, the Simply Wall St discounted cash flow model estimates a future cash flow value of $599.47, suggesting the shares trade about 33% below that level. Natera's investment in new product launches such as Fetal Focus NIPT, Signatera Genome, and AI-based biomarkers, along with its R&D pipeline, positions it to capture growth from long-term trends in personalized medicine and early detection, though tighter reimbursement rules or sustained high R&D spending could pressure profitability.

Coinbase Global is relaunching Coinbase Pro with Deribit integration as part of a unified Coinbase Global Exchange. The revamped Coinbase Pro will combine U.S. and international crypto derivatives, including options and perpetual futures, under one regulated platform. Institutional clients are expected to see consolidated spot and derivatives trading with shared liquidity and centralised risk management tools. The relaunch connects one of the deepest crypto options venues into Coinbase's existing institutional stack, from Prime to the new CFTC cleared Coinbase Clearing LLC scope. The test now is how quickly Coinbase reports take-up of Deribit options and perpetuals through Coinbase Prime once the unified exchange is live, and whether derivatives share of total transaction volume is broken out and starts to carry more weight in quarterly updates over the next few earnings cycles.

Almonty Industries has cleared the final regulatory hurdle for commercial operations at its Sangdong processing plant in South Korea, opening the door to tungsten concentrate sales under a long-term offtake agreement. More than 90% of Phase I output is already committed to Global Tungsten & Powders for 21 years, and the certification arrives while tungsten prices are described as being at historic highs. The stock has been volatile, with a 30 day share price return down 35.24% and a 7 day move lower by 11.42%, though the year to date share price return is 34.89% and the 1 year total shareholder return is 53.16%. Almonty closed at $11.87, while the most followed narrative points to a fair value of $15.26 using a 9.15% discount rate. The main condition for success is the ramp up and optimization of Sangdong and Los Santos, alongside effective use of the US$800m convertible notes and the Rwanda joint venture.

The European Union and China reached a preliminary agreement on Friday to cut Chinese hybrid vehicle exports to the bloc by more than half, offering relief to European automakers ahead of next week's Paris Motor Show. The deal could ease competitive pressure on Volkswagen, Stellantis and Renault, which are struggling with declining sales and growing competition from Chinese manufacturers, though details remain limited and Germany's VDA automotive association described it only as an initial positive signal. Chinese brands captured nearly 12% of Europe's new-car market in August, according to Dataforce, and EU imports of Chinese cars and light commercial vehicles surged almost 75% to nearly 770,000 units during January-August, with hybrids currently avoiding the additional EU tariffs imposed on Chinese-made battery-electric cars. European manufacturers face mounting financial pressure, as Mercedes-Benz reported an 8% decline in third-quarter car sales while Volkswagen recently lowered its profit outlook following a similar warning from BMW. The Paris Motor Show, running October 12-18, will highlight efforts to defend European market share through affordable electric vehicles and new partnerships, with Renault's Dacia brand showcasing its second-generation Spring electric car priced below €18,000 in France, Volkswagen presenting its ID. Tiguan alongside a strategy involving four smaller electric vehicles manufactured in Spain, and Stellantis displaying more than 60 vehicles across eight brands including a Citroën electric concept developed using technology from Chinese partner Leapmotor, while Chinese competitors BYD, XPeng and Zeekr will also showcase expanded lineups.

NextNav Inc. announced in October 2026 a partnership with AiRANACULUS to advance integrated sensing and communications across its licensed lower 900 MHz spectrum. The collaboration combines NextNav's ground-based 5G-powered 3D PNT network with AiRANACULUS's signal processing technology to enhance drone detection and counter-unmanned aircraft capabilities. The companies aim to reduce infrastructure needs for wide-area sensing while supporting digital airspace management and critical national security applications. The tie-up follows NextNav's August 2026 selection of Tiami Networks as a sensing ecosystem partner for 5G counter UAS trials in the same Santa Clara footprint, with both projects framing a catalyst around ISAC-based drone detection. NextNav's narrative projects $2.8 million revenue and $336.4 thousand earnings by 2029, assuming revenue will decrease by 11.5% per year and that earnings will rise by about $141.6 million from -$141.3 million today, while the central risk remains that FCC timing and commercialization of the 900 MHz asset could slip.